Perspective Therapeutics股价于2026年2月21日因成交量低上涨12.3%，分析师将其评为“买入”，目标为11.50美元。 Perspective Therapeutics shares rose 12.3% on Feb. 21, 2026, on low volume, as analysts rate it a "Buy" with a $11.50 target.

2026年2月21日,按低于平均交易量计算,透视治疗(CATX)股份上升12.3%至5.65美元。 Perspective Therapeutics (CATX) shares rose 12.3% to $5.65 on February 21, 2026, on lower-than-average trading volume. 该公司开发有针对性的癌症疗法,在1/2a阶段试验中有两个临床方案。 The company, developing targeted cancer therapies, has two clinical programs in Phase 1/2a trials. 分析员维持“Buy”共识,平均价格目标为11.50美元。 Analysts maintain a "Buy" consensus with an average price target of $11.50. 尽管收入较低,但股票显示出强劲的金融表现,包括流动性高、债务低和利润度量比同龄人好。 The stock shows strong financials, including high liquidity, low debt, and better profitability metrics than peers, despite lower revenue. 机构所有权为54.7%,反映了投资者的强烈信心,而内部所有权很低。 Institutional ownership at 54.7% reflects strong investor confidence, while insider ownership is low. 该库存比S&P 500更不稳定,但交易的P/E比率较低,表明可能估价过低。 The stock is more volatile than the S&P 500 but trades at a lower P/E ratio, suggesting potential undervaluation.